摘要
目的探索银屑病患者血浆可溶性尿激酶型纤溶酶原激活物受体(suPAR)水平与其疾病严重程度的关联性。方法选取2013年1月~2015年12月医院就诊的60例银屑病患者(患者组)和60例健康体检者(对照组)。酶联免疫吸附法(ELISA)测定患者组和对照组血浆suPAR水平,Kruskal-Wallis和Mann-Whitney U检验比较血浆suPAR差异。Spearmans's rho分析临床参数与血浆suPAR的相关性。结果患者组血浆suPAR(3.92±1.04 ng/ml)显著高于对照组(3.03±0.58 ng/ml,Z=13.05,P=0.009)。轻度患者(PASI<10)血浆suPAR(2.67±0.63 ng/ml)显著低于中度(10≤PASI≤20,3.90±1.67 ng/ml,Z=8.00,P=0.035)和重度患者(PASI>20,4.55±1.88 ng/ml,Z=48.5,P=0.031)。患者血浆suPAR与PASI呈正相关(r=0.264,P=0.041)。痛程>10年患者(n=35)血浆suPAR(4.43±1.98 ng/m1)显著高于病程<10年患者(n=25,3.41±0.69 ng/ml,Z=-2.064,P=0.035)。结论血浆suPAR与银屑病疾病严重程度呈正相关,suPAR可作为银屑病严重程度及疗效评估的指标之一,辅助临床诊断。
Objective To investigate the correlation between plasma-soluble urokinase plasminogen activator receptor （su- PAR） levels and disease severity in psoriasis patients. Method 60 psoriasis patients and 60 healthy controls were enrolled from Jan. 2013 to Dec. 2015 in the hospital. The plasma suPAR of all objects were measured by ELISA. Kruskal-Wallis and Mann-Whitney U test were used to compared plasma suPAR in the difference groups. Correlation between clinical data and plasma suPAR were analyzed by Spearmans＇s rho method. Result The plasma suPAR of psoriasis patients （3.92±1.74 ng/ml） were higher than controls （3.03 ± 1.08 ng/ml, Z= 13.05, P = 0. 009）. The plasma suPAR of mild patients （PASI〈 10） were lower than moderate patients （ 10 ≤ PASI≤ 20, 3.90 ± 1.67 ng/ml, Z= 8.00, P =0. 035 ） and severity patients （PASI〉 20,4.55±1.88 ng/ml, Z= 48.5, P = 0.031）. Positive correlation were found between plasma suPAR and psoriasis area and severity dndex （PASI） score （r= 0. 264, P = 0. 041）. The plasma suPAR of the patients with disease duration〉 10 years （n=35,4.43±1.98 ng/ml） were higher than the patients with disease duration%10 years （n=25,3.41±0.69 ng/ ml,Z=-2. 064,P=0. 035）. Conclusion There was a positive correlation between the plasma suPAR and psoriasis disease severity. The Plasma suPAR can be the biomarker of psoriasis disease severity. It facilitate the clinical diagnosis of psoriasis.
出处
《现代检验医学杂志》
CAS
2017年第2期41-44,共4页
Journal of Modern Laboratory Medicine
基金
陕西省科技攻关项目
项目编号2014K11-02-03-13
